vTv Therapeutics Appoints Edward P. Taibi To Board

​HIGH POINT, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated, to the vTv Board of Directors. Effective August 31, 2020, Mr. Taibi will serve a term through the date of the next annual meeting of the Company’s stockholders.

“Ed will add significant value as a vTv board member and will be a tremendous asset in helping to drive our near-and long-term goals,” said Steve Holcombe, CEO of vTv Therapeutics. “As a member of the senior leadership team at MacAndrews, we look forward to leveraging his keen insights and future contributions.”

Mr. Taibi has gained extensive business leadership experience over the course of his sixteen-year tenure at MacAndrews, advising on transformative business development opportunities, as well as large and complex capital markets and financing transactions. Prior to joining MacAndrews, Mr. Taibi served as a lawyer in the Mergers and Acquisitions group at Skadden, Arps, Slate, Meagher & Flom LLP.

“I am honored to join vTv Therapeutics’ Board of Directors,” said Edward P. Taibi. “I look forward to collaborating with vTv’s management team as we progress the development of the company’s pipeline of innovative clinical drug candidates that have the potential to significantly improve the lives of patients suffering with type 1 diabetes and Alzheimer’s disease.”

MacAndrews is a holding company with a portfolio of public and private companies in diverse industries. MacAndrews has been a significant investor in vTv and its predecessor companies for more than 20 years.

About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for adjunctive treatment for type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.